Abstract
Infectious diseases remain a major health problem and cause of death worldwide. A variety of radiopharmaceuticals are used for the imaging of infections and inflammation in the practice of nuclear medicine. Long-term clinical use has shown that the majority of radiolabeled probes cannot distinguish between inflammation and infection. Gallium-67-citrate binds to bacteria, but also to proteins ac-cumulating at both sterile inflammation and bacterial infection sites. Other agents are used to interact with receptors or domains on circu-lating and infiltrating leukocytes or to label them directly. However, these probes cannot distinguish between infection and inflammation because they are not specific to infectious micro-organisms. This review examines the recent developments and applications of radiola-beled specific agents, such as antiviral drugs, antifungal, antibiotics and antimicrobial peptides, to visualize infectious foci by targeting viruses, fungi or bacteria.
Keywords: Radiolabeled antibiotics, antimicrobial peptides, antiviral drugs, technetium-99m-ubiquicidin, scintigraphy, radiopharmaceuticals, inflammation, radiolabeled probes, Gallium-67-citrate, leukocytes
Current Pharmaceutical Design
Title: Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms
Volume: 18 Issue: 8
Author(s): Guillermina Ferro-Flores, Blanca E. Ocampo-Garcia and Laura Melendez-Alafort
Affiliation:
Keywords: Radiolabeled antibiotics, antimicrobial peptides, antiviral drugs, technetium-99m-ubiquicidin, scintigraphy, radiopharmaceuticals, inflammation, radiolabeled probes, Gallium-67-citrate, leukocytes
Abstract: Infectious diseases remain a major health problem and cause of death worldwide. A variety of radiopharmaceuticals are used for the imaging of infections and inflammation in the practice of nuclear medicine. Long-term clinical use has shown that the majority of radiolabeled probes cannot distinguish between inflammation and infection. Gallium-67-citrate binds to bacteria, but also to proteins ac-cumulating at both sterile inflammation and bacterial infection sites. Other agents are used to interact with receptors or domains on circu-lating and infiltrating leukocytes or to label them directly. However, these probes cannot distinguish between infection and inflammation because they are not specific to infectious micro-organisms. This review examines the recent developments and applications of radiola-beled specific agents, such as antiviral drugs, antifungal, antibiotics and antimicrobial peptides, to visualize infectious foci by targeting viruses, fungi or bacteria.
Export Options
About this article
Cite this article as:
Ferro-Flores Guillermina, E. Ocampo-Garcia Blanca and Melendez-Alafort Laura, Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315821
DOI https://dx.doi.org/10.2174/138161212799315821 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Current Therapeutic Options for Alzheimers Disease
Current Genomics Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Mechanisms of HIV-1 Neurotropism
Current HIV Research Antiviral Strategies: The Present and Beyond
Current Molecular Pharmacology COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Targeting Cytokines, Chemokines and Adhesion Molecules in Rheumatoid Arthritis
Current Rheumatology Reviews The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Impact of Latent Viral Infections in Mechanically Ventilated Patients
Current Respiratory Medicine Reviews 14-3-3 Protein in CSF Reflects SIV-Mediated Pre-Synaptic Damage
Current HIV Research Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research The Cellular Protective Effects of Rosmarinic Acid: From Bench to Bedside
Current Neurovascular Research Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Virus-Based RNA Silencing Agents and Virus-Derived Expression Vectors as Gene Therapy Vehicles
Recent Patents on Biotechnology